Abstract
To compare the effectiveness of intramuscular (IM) olanzapine and typical IM antipsychotics in naturalistically treated acutely agitated patients with schizophrenia or acute mania. During the acute phase, 2011 inpatients (including emergency settings) were assessed at 2, 24 and 72 h, and 7 days following initial injection and on oral antipsychotic transition. Mean change in agitation was assessed via Positive and Negative Symptom Scale-Excited Component (PANSS-EC) and Clinical Global Impressions-Severity (CGI-S) scores. Response (> or = 40% reduction in baseline PANSS-EC score) was analysed using logistic regression. Significantly greater decreases in PANSS-EC and CGI-S scores were observed in patients receiving IM olanzapine (n = 1294) as their first injection compared with patients receiving other IM antipsychotics (n = 717) (P<0.05; 2 h: effect size 0.1); IM haloperidol treatment (all assessments, P<0.05); and IM zuclopenthixol treatment (2 h, P<0.001). Higher response rates were observed with IM olanzapine compared with other IM antipsychotics at 24 and 72 h, and 7 days (P<0.05). IM olanzapine was associated with fewer extrapyramidal side effects compared with other assessed IM antipsychotics. IM olanzapine provided somewha...Continue Reading
References
Jan 1, 1990·Schizophrenia Bulletin·S R Kay, S Sevy
Jul 1, 1969·Health Physics·N Ohen, T J Kneip
Nov 30, 1999·Psychiatric Services : a Journal of the American Psychiatric Association·R L Binder, D E McNiel
Jun 30, 2001·The American Journal of Psychiatry·P WrightA Breier
Jul 31, 2001·Journal of Clinical Psychopharmacology·K MeehanA Breier
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karena M MeehanAlan Breier
May 2, 2002·Archives of General Psychiatry·Alan BreierPadraig Wright
Jul 18, 2003·Clinical Therapeutics·Padraig WrightAlan Breier
Mar 15, 2005·General Hospital Psychiatry·Horacio PrevalAndrew Francis
May 16, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·L SanV Pérez
Apr 3, 2007·Annals of General Psychiatry·Chris J BusheMathew Mathew
Aug 22, 2007·Human Psychopharmacology·Franca CentorrinoJohn P Houston
Sep 11, 2007·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Jeffrey DanielDavid Castle
Dec 29, 2007·The Journal of Clinical Psychiatry·Leslie Citrome
Citations
Jun 30, 2009·International Journal of Clinical Practice·R ChandrasenaT Treuer
May 13, 2015·PharmacoEconomics·Gregory KruseJohn M Fastenau
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Jul 14, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·E PerrinUNKNOWN OBS-IM investigators group
Jul 28, 2016·Schizophrenia Research·Mantana Kittipeerachon, Warawat Chaichan
Feb 26, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Marina GarrigaEduard Vieta
Apr 18, 2018·International Clinical Psychopharmacology·Monika EdlingerAlex Hofer
Sep 3, 2013·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Peter BosanacDavid Castle
May 18, 2010·Journal of Clinical Psychopharmacology·Wen-Yu HsuNan-Ying Chiu
Apr 24, 2013·Journal of Clinical Psychopharmacology·Celia MantovaniCristina Marta Del-Ben
Mar 8, 2019·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Leonardo BaldaçaraTeng C Tung